Though life sciences companies see value across the full supply chain, it’s the last mile that matters the most to the customer. With this in mind, we surveyed 150+ pharma logistics leaders to learn more about the key
challenges, solutions and trends impacting the last mile of the life
sciences supply chain.
- Analysis of what causes the most last mile disruptions and how firms are addressing these issues
- An overview of our respondents top strategic priorities
- Facts & figures that outline where cold chain leaders are looking to invest in 2018 & 2019
Blockchain & The Temperature Controlled Supply Chain: Is It Time For Pharma Logistics Leaders In Canada to Embrace Blockchain?
As 2019 CCGF Canada speaker Nedal Ismail, Professor and Program Coordinator Bachelor of Commerce, Supply Chain Management & Management Studies, The Business School, Humber Institute of Technology & Advanced Learning, puts it, though "it is not immediately apparent if blockchain will bring an incremental change (i.e. a marginal improvement in existing processes), or a disruptive change (one that will completely change the way the business is conducted), one thing is clear: blockchain stands to transform pharma logistics over the next decade. From enabling increased transparency, security, communication and efficiency, the potential benefits of blockchain seem limitless.
In this in-depth report, we demystify blockchain by shedding light on:
- Current use cases and applications of blockchain in pharma logistics both here in Canada and abroad
- Key barriers to adoption and challenges associated with blockchain
- The future of blockchain technology and how it could potentially be used to optimize the pharma supply chain in years to come
- Why Canada is becoming a global hub for blockchain innovation both within life sciences and beyond
IQPC is pleased to announce the new Keynote speaker for the 17th Cold Chain Global Forum Canada! Joining the all-star speaker faculty alongside Canadian Blood Services, Sandoz Canada, and Roche Diagnostics is Kimby Barton, Director of the Health Product and Licensing Division (HPIL), Health Products Compliance Directorate at Health Canada’s Regulatory Operation and Regions Branch.
View the press release to learn more about Kimby Barton and her Keynote session.